Meeting
2020 ASCO Virtual Scientific Program
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
Presenter
Keunchil Park, MD, PhD
Samsung Medical Center, Sungkyunkwan University School of Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02609776
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9512)
DOI
10.1200/JCO.2020.38.15_suppl.9512
Abstract #
9512
Poster Bd #
278
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
Speaker: Sai-Hong Ignatius Ou, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.
Speaker: Anna Rachel Minchom, BCh, MB, MD, MRCP
Videos & Slides
2024 ASCO Breakthrough
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
Speaker: Makoto Nishio, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
Speaker: Helena Alexandra Yu, MD